Immune-checkpoint inhibitors: long-term implications of toxicity
The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance
S Bagchi, R Yuan, EG Engleman - Annual Review of Pathology …, 2021 - annualreviews.org
Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the …
A Marabelle, M Fakih, J Lopez, M Shah… - The Lancet …, 2020 - thelancet.com
Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of …
response to immune checkpoint blockade. We prospectively explored the association of …
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
JM Banales, JJG Marin, A Lamarca… - Nature reviews …, 2020 - nature.com
Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …
The challenges of tumor mutational burden as an immunotherapy biomarker
DL Jardim, A Goodman, D de Melo Gagliato… - Cancer cell, 2021 - cell.com
Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics
Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many
cancer indications. This review provides an update on ICIs approved by the Food and Drug …
cancer indications. This review provides an update on ICIs approved by the Food and Drug …
Tumor mutational burden as a predictive biomarker in solid tumors
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
Pembrolizumab in patients with microsatellite instability–high advanced endometrial cancer: results from the KEYNOTE-158 study
DM O'Malley, GM Bariani, PA Cassier… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Pembrolizumab demonstrated durable antitumor activity in patients with
previously treated, advanced microsatellite instability–high or mismatch repair–deficient …
previously treated, advanced microsatellite instability–high or mismatch repair–deficient …
[HTML][HTML] Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
M Maio, PA Ascierto, L Manzyuk, D Motola-Kuba… - Annals of …, 2022 - Elsevier
Background Pembrolizumab demonstrated durable antitumor activity in 233 patients with
previously treated advanced microsatellite instability high (MSI-H) or mismatch repair …
previously treated advanced microsatellite instability high (MSI-H) or mismatch repair …
Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE …
PURPOSE Pembrolizumab monotherapy has shown antitumor activity in patients with small-
cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study …
cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study …